Professional Documents
Culture Documents
ATPM Requirement For Quality
ATPM Requirement For Quality
(ATMP)
Ivana Haunerova
Day 2 – 24. 2. 2021
This project has received funding from the European Union’s Horizon 2020 research and innovation programme
under grant agreement No. 825881
Summary
29.03.2021 | 2
CSA-STARS 2
Briefly about GMP
29.03.2021 | 3
CSA-STARS 3
Briefly about GMP
• EudraLex - The Rules Governing Medicinal Products in the European Union - Volume 4 -
Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal
Products (GMP for ATMP)
• https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-
4/2017_11_22_guidelines_gmp_for_atmps.pdf
29.03.2021 | 5
CSA-STARS 5
Briefly about GMP
29.03.2021 | 8
CSA-STARS 8
Drug Product
Final Product
• = drug substance with excipients (in its final combination) in the primary container
29.03.2021 | 9
CSA-STARS 9
Starting material ... „Where does a GMP start?“
• In case of products consisting of viruses or viral vectors, the starting materials shall be the components
from which the viral vector is obtained, i.e. the master virus vector seed or the plasmids used to transfect
the packaging cells and the master cell bank of the packaging cell line.
• In the case of products consisting of plasmids, non-viral vectors and genetically modified microorganism(s)
other than viruses or viral vectors, the starting materials shall be the components used to generate the
producing cell, i.e. the plasmid, the host bacteria and the master cell bank of recombinant microbial
cells.
• In the case of genetically modified cells, the starting materials shall be the components used to obtain the
genetically modified cells, i.e. the starting materials to produce the vector, the vector and the human or
animal cells.
• The principles of good manufacturing practice shall apply from the bank system used to produce the vector
or 29.03.2021
the plasmid| that are used as starting materials. 10
CSA-STARS 10
How to present quality data to the regulatory authority?
29.03.2021 | 11
CSA-STARS 11
CTD format of the dossier
29.03.2021 | 13
CSA-STARS 13
CTD format of the dossier
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s)
3.2.P.3.2 Batch Formula
3.2.P.3.3 Description of Manufacturing Process and Process Controls
3.2.P.3.4 Controls of Critical Steps and Intermediates
3.2.P.3.5 Process Validation and/or Evaluation
3.2.P.4 Control of Excipients
3.2.P.4.1 Specifications
3.2.P.4.2 Analytical Procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of Specifications
3.2.P.4.5 Excipients of Human or Animal Origin
3.2.P.4.6 Novel Excipients
29.03.2021 | 15
CSA-STARS 15
CTD format of the dossier
29.03.2021 | 16
CSA-STARS 16
CTD format of the dossier
3.2.A APPENDICES
3.2.A.1 Facilities and Equipment
3.2.A.2 Adventitious Agents Safety Evaluation
3.2.A.3 Excipients
3.2.R REGIONAL INFORMATION
3.3 LITERATURE REFERENCES
29.03.2021 | 17
CSA-STARS 17
Relevant guidelines
• https://www.ema.europa.eu/en/human-regulatory/research-development/advanced-
therapies/guidelines-relevant-advanced-therapy-medicinal-products
29.03.2021 | 18
CSA-STARS 18
Relevant guidelines
• Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products
in clinical trials EMA/CAT/852602/2018 (draft – closed public consultation)
• Guideline on human cell-based medicinal products (EMEA/CHMP/410869/2006)
• Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products (EMA/CAT/80183/2014)
• Raw materials derived from animal- or human-derived material (blood):
• Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human
and Veterinary Medicinal Products (EMEA/410/01)
• Ph. Eur. 5.2.12 and Ph. Eur. 5.1.7
• Guideline on 1253 Plasma-Derived Medicinal Products (EMA/CHMP/BWP/706271/2010)
• European Pharmacopoeia
• 5.2.12 Raw materials for the production of cell-based and gene therapy medicinal products
• 2.6.27 Microbiological control of cellular products
• 2.6.1. Sterility
• ... etc.
29.03.2021 | 19
CSA-STARS 19
Risk-based approach
• Risks caused by character of the starting and raw materials, by level of manipulation
during the manufacturing process, by control strategy, by level of manipulation prior to
administration, by level of knowledge of the product itself.
29.03.2021 | 20
CSA-STARS 20
Risk-based approach
Risk profiling
29.03.2021 | 21
CSA-STARS 21
CTD format of the dossier
29.03.2021 | 23
CSA-STARS 23
CTD format of the dossier
Critical parameter?
29.03.2021 | 25
CSA-STARS 25
ATMP Manufacture
29.03.2021 | 26
CSA-STARS 26
Manufacturing process – ATMP‘s specificity
29.03.2021 | 27
CSA-STARS 27
Starting materials
• Ph.Eur. 5.2.12 Raw materials for the production of cell based and gene therapy medicinal
products
• Ph. Eur. 5.1.7 Viral safety
GMP-grade
• Not sufficient claim
• What does it ensure?
29.03.2021 | 32
CSA-STARS 32
Raw materials
How
Own is it tested
release testing
Ask forismaximum (parameters, methods,
prior its usage.
What its source and
information
related risks from the
with respect to criteria)?
manufacturer/vendor.
microbial, viral and TSE/BSE
Include inactivation steps,
safety? What
Whatshould
can
if possible. ATMP Inspection
Is the at the
manufacturer
manufacturer manufacturer/vendor
site of its
know?
do? reliable?
manufcature.
Market
Does an
alternative
monitoring. Aggreement
Is there a riskwith
of its
material exist? the vendor.
shortage or changes in
production?
Process validation
29.03.2021 | 34
CSA-STARS 34
Process development
29.03.2021 | 35
CSA-STARS 35
Process development – comparability study
• Comparability study
• Comparison of process parameters
• Comparison of produced material
https://parexel-academy.com
• Characterization methods, release data, stability data
• Side-by-side analysis and split samples when possible
• Extent of studies depends on introduced change, phase of development and technical/ethical possibilities
• Non-clinical/clinical data may be needed
29.03.2021 | 36
CSA-STARS 36
Process development
zdroj: https://cellgenix.com
29.03.2021 | 37
CSA-STARS 37
Manufacture – automatic processes
• Advantage: consistency of the production, possibility of manufacture close to the patient (in time and
place)
• Disadvantage: limited possibility for process control and optimalization, risk for loss of consistent control
(decentralization)
29.03.2021 | 38
CSA-STARS 38
CTD format of the dossier
• Characterization methods
• Basis for release testing strategy
• Necessary for demonstration of comparability
29.03.2021 | 41
CSA-STARS 41
CTD format of the dossier
29.03.2021 | 43
CSA-STARS 43
CTD format of the dossier
29.03.2021 | 45
CSA-STARS 45
CTD format of the dossier
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s)
3.2.P.3.2 Batch Formula
3.2.P.3.3 Description of Manufacturing Process and Process Controls
3.2.P.3.4 Controls of Critical Steps and Intermediates
3.2.P.3.5 Process Validation and/or Evaluation
3.2.P.4 Control of Excipients
3.2.P.4.1 Specifications
3.2.P.4.2 Analytical Procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of Specifications
3.2.P.4.5 Excipients of Human or Animal Origin
3.2.P.4.6 Novel Excipients
29.03.2021 | 46
CSA-STARS 46
CTD format of the dossier
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s)
3.2.P.3.2 Batch Formula
3.2.P.3.3 Description of Manufacturing Process and Process Controls
3.2.P.3.4 Controls of Critical Steps and Intermediates
3.2.P.3.5 Process Validation and/or Evaluation
3.2.P.4 Control of Excipients
3.2.P.4.1 Specifications
3.2.P.4.2 Analytical Procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of Specifications
3.2.P.4.5 Excipients of Human or Animal Origin
3.2.P.4.6 Novel Excipients
29.03.2021 | 47
CSA-STARS 47
CTD format of the dossier
29.03.2021 | 48
CSA-STARS 48
3.2.P.5 Control of Drug Product
Specifications = defined list of cotrols performed routinely at the time of product release
(and stability)
29.03.2021 | 49
CSA-STARS 49
3.2.P.5 Control of Drug Product
Parameter Analytical method Acceptance criteria
Appearance, volume Visual control Min. 5 ml of yellow suspension
without extraneous particles
Cell concentration Ph. Eur. 2.7.29 2-6 x 106 cells/ ml
29.03.2021 | 51
CSA-STARS 51
3.2.P.5 Control of Drug Product
29.03.2021 | 52
CSA-STARS 52
Batch release prior to obtaining the results of quality control tests
29.03.2021 | 53
CSA-STARS 53
Sterility testing
• General monograph... Ph. Eur. 5.1.6 Alternative methods for control of microbiological
quality
29.03.2021 | 54
CSA-STARS 54
Ph. Eur. 2.6.27 Microbial examination of cell-based preparations
29.03.2021 | 55
CSA-STARS 55
Administration of the product with results out of specifications
29.03.2021 | 56
CSA-STARS 56
CTD format of the dossier
29.03.2021 | 57
CSA-STARS 57
CTD format of the dossier
29.03.2021 | 58
CSA-STARS 58
CTD format of the dossier
29.03.2021 | 59
CSA-STARS 59
3.2.P.8 Stability
29.03.2021 | 60
CSA-STARS 60
CTD format of the dossier
3.2.A APPENDICES
3.2.A.1 Facilities and Equipment
3.2.A.2 Adventitious Agents Safety Evaluation
3.2.A.3 Excipients
3.2.R REGIONAL INFORMATION
3.3 LITERATURE REFERENCES
29.03.2021 | 61
CSA-STARS 61
CTD format of the dossier
3.2.A APPENDICES
3.2.A.1 Facilities and Equipment
3.2.A.2 Adventitious Agents Safety Evaluation
3.2.A.3 Excipients
3.2.R REGIONAL INFORMATION
3.3 LITERATURE REFERENCES
29.03.2021 | 62
CSA-STARS 62
CTD format of the dossier
3.2.A APPENDICES
3.2.A.1 Facilities and Equipment
3.2.A.2 Adventitious Agents Safety Evaluation
3.2.A.3 Excipients
3.2.R REGIONAL INFORMATION
3.3 LITERATURE REFERENCES
29.03.2021 | 63
CSA-STARS 63
ATMP and medical devices
• Documentation:
• Logic presentation
• Unambiquious
• In detail
29.03.2021 | 66
CSA-STARS 66